An insomnia treatment linked to sleepwalking and sleep driving should stay on the market according to the Australian Therapeutic Good Administration (TGA).
Unilife’s Q3 revenues slide as Sanofi milestones end
Syringe maker Unilife saw its revenue fall in the third quarter on a lack of milestone payments and its exit from the contract manufacturing sector.
Unilife reports growing interest in prefilled syringe; execs invest
US delivery device maker Unilife has reported growing drug industry interest in its Unifill prefilled syringe range.
German Sanofi plant receives FDA cGMP warning letter
Sanofi-aventis has received an FDA warning letter after the agency identified violations of cGMP at its Frankfurt am Main, Germany plant.
Genzyme to sell intermediates biz to ICIG
Genzyme will sell its pharmaceutical intermediates business to International Chemical Investors Group (ICIG).
Sopharma to invest BGN70m in new plant
Bulgarian drugmaker Sopharma will invest BGN70m ($47m) in the construction of a new manufacturing plant in a further bid to drive export growth.
Genzyme values itself at $22.7bn, $20 per share higher than Sanofi bid
US Biotechnology firm Genzyme predicts 2011 earnings in $4.30 to $4.60 range, which would make it worth $89 per share or $22.7bn.
Venus to supply docetaxel to Thailand
Venus Remedies is supplying docetaxel to Thailand after a compulsory license was issued to make the drug more affordable.
Sanofi discontinuing old insulin pens in UK
Sanofi-Aventis is discontinuing use of old insulin pen devices in the UK in response to NPSA guidance.
Merck Millipore launched after $7bn takover
Germany’s Merck KGaA has completed its $7bn (€b5.2n) acquisition of Millipore, unveiling plans to target “high-growth, high-margin” bio-research and bio-production markets.
Sanofi said to be planning $20bn acquisition in US
Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.
Sanofi’s China R&D centre up and running
Sanofi Aventis’ expanded R&D centre in China opened for business last week, further building the French drugmakers presence in the country.
Patheon posts Q1 loss, but upbeat on 2010; Orexigen deal
Patheon attributes Q1 loss to charges and plant closure costs and says there has been “an encouraging increase in new sales activity” in calendar 2010.
Sanofi boosts syringe and vacc capacity at French plant
Sanofi Aventis has revamped operations at its sterile injectables plant in Le Trait, France, adding three new production units that double syringe making capacity and diversify its vaccine manufacturing capability.
Sanofi, Teva and Ratiopharm raided in EC competition probe
French drug major Sanofi Aventis, Israel's Teva Pharmaceutical Industries and Germany’s Ratiopharm were raided by European Commission (EC) competition officials yesterday as part of an ongoing investigation.